Cargando…
Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?
Mantle cell lymphoma (MCL), a type of B-cell non-Hodgkin lymphoma characterized by the t(11;14)(q13q32) translocation, is a clinically heterogenous disease which can range from indolent to highly aggressive. Numerous prognostic factors have been identified, including blastoid histology, the Mantle C...
Autores principales: | Hammons, Lindsay, Fenske, Timothy S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324979/ https://www.ncbi.nlm.nih.gov/pubmed/35887631 http://dx.doi.org/10.3390/jpm12071134 |
Ejemplares similares
-
Current trials for frontline therapy of mantle cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2018) -
Mantle cell lymphoma: a model for risk-adapted treatment approach
por: Kim, Seok Jin
Publicado: (2014) -
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022) -
Advances and Personalized Approaches in the Frontline Treatment of T-Cell Lymphomas
por: Angelos, Mathew G., et al.
Publicado: (2022) -
Mantle cell lymphoma and its management: where are we now?
por: Ladha, Abdullah, et al.
Publicado: (2019)